Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: anti-inflammatory diet for Systemic Lupus Erthematosus (SLE)

To study the effect of anti-inflammatory diet on clinical and biological outcomes in lupus

Official registry: https://clinicaltrials.gov/study/NCT07713940 · University of California, San Diego · enrollment listed as 36

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are anti-inflammatory diet. The registry lists allocation as na. To study the effect of anti-inflammatory diet on clinical and biological outcomes in lupus

They plan to enroll about 36 people at La Jolla. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous

Interventions: anti-inflammatory diet

Primary outcome (registry wording): PROMIS pain interference

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • patients who meet the 2019 EULAR/ACR Classification Criteria for SLE
  • patients who are on Cellcept or Myfortic for at least 3 months prior to screening
  • patients with a score of ≥55 on the Patient Reported Outcomes Measurement Information System (PROMIS) Pain interference scale

Public study contact (from the registry)

Monica Guma, MD, PhD

858-822-6523

mguma@health.ucsd.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseBethesda, Maryland
Immune System Related Kidney Disease

Kidney diseases related to the immune system include, nephrotic syndrome, glomerulonephritis, membranous nephropathy, lupus nephritis, and nephritis associated with connective tissue disorders. This study will allow researchers to admit and follow patients suffering from autoimmune diseases of the kidney.

NCT00001979 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

RecruitingPhase 2Loma Linda, California
Phase 2: testing Obinutuzumab for Lupus Nephritis

This phase II, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study is designed to measure the safety, how well it works and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

NCT05039619 · Official ClinicalTrials.gov record · Hoffmann-La Roche

FAQ about this NCT record

Is NCT07713940 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07713940?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07713940?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary